"Your labs are normal" may be the most frustrating sentence in Hashimoto's thyroiditis. You still have debilitating fatigue. Your brain fog hasn't cleared. The lab results say TSH 3.2: within reference range. This guide explains why "within reference range" and "optimal for Hashimoto's" are not the same thing. These are specific functional targets backed by published research. Bring this to your physician and work toward them together. Do not adjust thyroid medications independently.
Why Are Standard Lab Ranges Wrong for Hashimoto's?
Standard laboratory reference ranges are calculated to include approximately 95% of a tested population. The underlying assumption is that this population is healthy. For thyroid function, this assumption is flawed in a specific, well-documented way.
How Was the "Normal" TSH Range Established?
The TSH reference range of 0.4-4.5 mIU/L was derived from populations not screened to exclude thyroid disease. Studies that systematically excluded people with thyroid antibodies, subclinical hypothyroidism, and undetected autoimmune thyroid disease consistently produce a narrower TSH distribution. The upper normal limit in those cleaner populations falls around 2.5 mIU/L, not 4.5.
The American Association of Clinical Endocrinologists (AACE) recommended a narrower TSH target range of 0.3-3.0 mIU/L as far back as 2002. The 2012 American Thyroid Association (ATA) guidelines for Hashimoto's patients on levothyroxine recommend targeting TSH in the lower half of the normal range for patients who remain symptomatic.
The practical consequence: a patient with TSH 3.5 reporting persistent fatigue and brain fog may be told their labs are "normal." Evidence consistently shows TSH 3.5 in a Hashimoto's patient is associated with significantly worse symptom burden than TSH 1.5 in the same patient.
What Is the Optimal TSH for Hashimoto's?
Standard lab range: 0.4-4.5 mIU/L Functional target for Hashimoto's: 1.0-2.5 mIU/L On levothyroxine with persistent symptoms: 1.0-2.0 mIU/L
Why Does TSH Below 2.5 Matter?
Biondi and Wartofsky (2014, Endocrine Reviews) reviewed the controversy around TSH reference ranges in thyroid disease patients. They concluded that for patients on levothyroxine who remain symptomatic, targeting the lower half of the normal range is associated with better quality-of-life outcomes.
The ATA 2012 guidelines state explicitly that for patients on thyroid hormone therapy who report persistent symptoms, trialing a lower TSH target is a reasonable approach. This is established clinical guidance, not alternative medicine.
Subclinical hypothyroidism research (TSH 4.5-10, normal T4) consistently shows elevated cardiovascular risk, dyslipidemia, and cognitive impairment. TSH 3.5 and TSH 1.5 are not equivalent for patient outcomes.
If your TSH is 3.2 and your physician says it is "normal," you can request: "Based on ATA guidelines for Hashimoto's patients, could we trial a target TSH of 1.0-2.0 and assess symptom response?" That is a physician-supervised conversation, not a demand for a medication change.
What Is the Optimal Free T4 for Hashimoto's?
Free T4 (unbound thyroxine) is the principal output of the thyroid gland. Measuring it, not just TSH, matters because TSH can normalize while T4 remains suboptimal.
Standard range: approximately 0.8-1.8 ng/dL (varies by lab) Functional target: upper half of the reference range, approximately 1.3-1.8 ng/dL in most lab systems
A Free T4 in the lower half (for example, 0.9 ng/dL in a range of 0.8-1.8) means the available substrate for conversion to Free T3 is limited, even if TSH appears adequate.
Why Do Some Patients Need Direct T3?
The DIO2 Thr92Ala polymorphism, present in approximately 12-15% of the population, impairs cellular T4 to T3 conversion. Patients with this variant may have optimal Free T4 on levothyroxine but still have intracellular T3 deficiency. This explains persistent symptoms in a meaningful subset of well-treated Hashimoto's patients. For these patients, adding liothyronine (T3) or switching to desiccated thyroid extract (T4+T3) is an evidence-informed option referenced in ATA guidelines.
What Is the Optimal Free T3 Level?
Free T3 (unbound triiodothyronine) is the metabolically active thyroid hormone. T3 binds receptors on virtually every cell, regulating metabolism, energy, temperature, cognition, and gut motility. Free T4 must be converted to Free T3 to have physiological effect.
Standard range: approximately 2.3-4.2 pg/mL (varies; some labs 2.0-4.4) Functional target: upper third of the reference range, approximately 3.5-4.2 pg/mL in most lab systems
A Free T3 of 2.4 pg/mL is technically within the 2.3-4.2 reference range. It is also near the bottom of the distribution. The fatigue, cognitive impairment, and cold intolerance that many Hashimoto's patients experience despite "normal" labs are frequently explained by FT3 in the lower portion of the range.
Why some patients need direct T3
Patients with DIO2 polymorphisms, chronic inflammation, iron deficiency, or high reverse T3 may not adequately convert Free T4 to Free T3 despite optimal levothyroxine dosing. Adding liothyronine (T3) or switching to desiccated thyroid extract is an evidence-informed option discussed in ATA guidelines. If your Free T4 is in the upper half but Free T3 remains in the lower third and you have persistent symptoms, discuss this with your endocrinologist.
What Is Reverse T3 and Why Does It Matter?
Reverse T3 (rT3) is a metabolically inactive isomer of T3, produced from T4 by the DIO3 enzyme. In a healthy system, small amounts are produced and rapidly cleared. Under physiological stress, the body shunts T4 toward rT3: a conservation mechanism that reduces metabolic rate during illness.
Standard range: 9.2-24.1 ng/dL Functional target: FT3:rT3 ratio above 20 (with FT3 in pg/mL and rT3 in ng/dL; confirm units with your lab)
What Drives High Reverse T3?
High rT3 results from: chronic illness and systemic inflammation, iron deficiency, prolonged caloric restriction, high cortisol, and selenium deficiency. A high rT3 with a low FT3:rT3 ratio means inactive rT3 is competing with FT3 at the T3 receptor, producing cellular hypothyroid symptoms with labs that don't obviously explain them.
Address the underlying drivers: correct iron deficiency, reduce systemic inflammation, optimize selenium. Reverse T3 typically normalizes as these are corrected.
How Do You Read TPO Antibody Results?
Anti-thyroid peroxidase antibodies (TPO-Ab) are the primary diagnostic marker for Hashimoto's thyroiditis.
Standard lab range: below 35 IU/mL (negative) In Hashimoto's: typically 100-2,000+ IU/mL at diagnosis
The absolute TPO-Ab value at a single timepoint matters less than the trajectory over time:
- Declining over 6-12 months on protocol: positive response signal
- Stable but not declining: partial response; consider protocol optimization
- Rising year over year: active, progressive autoimmune damage; intervention is needed
A reduction of 20% or more from baseline over 6 months is the threshold used in clinical trials (including the CATALYST selenium trial) to define a meaningful response.
Key finding: Selenium and TPO antibodies
The CATALYST trial (2019) and multiple subsequent RCTs confirm that selenium supplementation at 200 mcg/day reduces TPO antibodies by 40-55% in Hashimoto's patients over 6-12 months. This is the Grade A intervention for antibody reduction. See the selenium for Hashimoto's guide for the full evidence breakdown.
What Are Thyroglobulin Antibodies (TgAb)?
Anti-thyroglobulin antibodies target thyroglobulin, the protein backbone from which thyroid hormones are cleaved. TgAb is often elevated alongside TPO-Ab, but approximately 10% of Hashimoto's patients have elevated TgAb with normal TPO-Ab: the seronegative or TgAb-predominant variant. Relying only on TPO-Ab will miss this group entirely.
Standard lab range: below 20 IU/mL Clinical goal: declining trend over time, same approach as TPO-Ab
TgAb also interferes with thyroglobulin (Tg) measurement used in thyroid cancer surveillance. Elevated TgAb makes Tg an unreliable tumor marker, important context for anyone who has had thyroid cancer treatment alongside Hashimoto's.
What Vitamin D Level Should Hashimoto's Patients Target?
The conventional "sufficient" threshold for vitamin D [25(OH)D] is 30 ng/mL, adequate for bone health. For autoimmune disease management, the evidence supports a substantially higher target.
Standard lab range: 30-100 ng/mL (sufficient at above 30) Functional target for Hashimoto's: 50-70 ng/mL
Why Is the Autoimmune Target Higher Than "Sufficient"?
The VITAL Trial (2022, NEJM, n=25,871): the largest randomized trial of vitamin D3 supplementation documented a 22% reduction in autoimmune disease incidence in the supplementation group at 5 years. The protective effect was most pronounced at serum levels sustaining adequate suppression of inflammatory cytokines, requiring 25(OH)D above 40-50 ng/mL.
The vitamin D receptor (VDR) on regulatory T cells (Tregs) upregulates Treg differentiation and suppression of autoreactive T cells. The dose-response for this immune effect requires serum levels above 50 ng/mL, well above the bone-health threshold. Vitamin D toxicity (hypercalcemia) requires sustained 25(OH)D above 150 ng/mL, providing a very large safety window.
Why Does Ferritin Matter for Thyroid Function?
Iron is a required cofactor for thyroid peroxidase (the enzyme making thyroid hormones) and for the deiodinase enzymes converting T4 to active T3. Ferritin below 70 ng/mL is functionally deficient for thyroid hormone synthesis and conversion, even when technically "within reference."
Standard lab range: 13-150 ng/mL (women), 24-336 ng/mL (men) Functional target for Hashimoto's: above 70-80 ng/mL
At ferritin below 30 ng/mL: thyroid peroxidase activity is impaired, T4 to T3 peripheral conversion is reduced, and telogen effluvium (hair shedding) is triggered independently of hypothyroidism. A significant subset of Hashimoto's patients who feel "still hypothyroid" on adequate levothyroxine have ferritin in the 20-60 ng/mL range. Correcting to above 70 ng/mL can produce meaningful symptom improvement without any medication change.
⚠ Ferritin is an acute-phase reactant
In active Hashimoto's inflammation, ferritin may appear falsely normal or elevated even when iron stores are functionally depleted. A full iron panel (serum ferritin, serum iron, TIBC, and transferrin saturation) is needed to interpret iron status accurately. Transferrin saturation below 20% indicates insufficient iron delivery to tissues regardless of what ferritin shows. Do not supplement iron without laboratory confirmation of deficiency.
What Is the Optimal Iron Panel for Hashimoto's?
Request the full panel, not just ferritin. Serum iron and TIBC together reveal transferrin saturation. Functional target: transferrin saturation 25-35%. Below 20% indicates iron delivery to tissues is insufficient, regardless of what ferritin shows.
What Selenium Level Should You Target?
Serum selenium is not included in standard thyroid panels, but selenium status is one of the most clinically significant nutritional variables in Hashimoto's thyroiditis. Selenium is a structural component of the glutathione peroxidase enzymes that neutralize hydrogen peroxide generated during thyroid hormone synthesis, and of the deiodinase enzymes (DIO1, DIO2) that regulate T3 production.
Standard reference range: 70-150 mcg/L Functional target for Hashimoto's: 120-150 mcg/L
Low-normal selenium (70-90 mcg/L) is sufficient to prevent clinical selenium deficiency (Keshan disease) but insufficient for optimal selenoprotein synthesis in the context of elevated oxidative demand from autoimmune thyroid disease. The CATALYST trial dose of 200 mcg/day selenomethionine targets the upper portion of the selenium range in deficient patients. See the selenium for Hashimoto's guide for the complete evidence breakdown.
What Should Your hs-CRP Be?
High-sensitivity C-reactive protein (hs-CRP) is produced by the liver in response to IL-6 and other inflammatory cytokines. In Hashimoto's, where elevated IL-6, TNF-alpha, and IL-17 are part of the disease process, hs-CRP provides a practical window into how much systemic inflammation is ongoing.
Standard normal: below 3.0 mg/L (cardiovascular risk threshold) Functional target for autoimmune disease management: below 1.0 mg/L
The 3.0 mg/L threshold was set for cardiovascular risk stratification, not autoimmune disease management. A Hashimoto's patient with hs-CRP at 2.5 mg/L is "normal" by that measure but is experiencing significant ongoing inflammation correlated with worse symptom burden and higher antibody levels.
The Abbott et al. (2019) AIP diet trial in Hashimoto's documented a 29% reduction in hs-CRP in the AIP group. Omega-3 at therapeutic dose (2-3g EPA+DHA/day) consistently reduces hs-CRP by 20-35% across multiple RCTs. If your hs-CRP is above 1.5 mg/L, anti-inflammatory dietary and supplement interventions are your highest-leverage opportunity. See the AIP diet for Hashimoto's guide.
What Is the Optimal Homocysteine Level?
Elevated homocysteine indicates deficiency of B12, B9 (folate), or B6: co-factors required to clear this amino acid through the remethylation and transsulfuration pathways.
Standard range: 5-15 mcmol/L Functional target: below 8 mcmol/L
Autoimmune gastritis, inflammation of the stomach lining, occurs in approximately 20-30% of Hashimoto's patients. It destroys parietal cells, reducing intrinsic factor production, which is essential for B12 absorption. The result is B12 malabsorption and eventual deficiency, elevating homocysteine and producing neurological symptoms (fatigue, brain fog, peripheral neuropathy) that compound hypothyroid symptoms.
Homocysteine above 10 mcmol/L warrants B12 testing. Patients with confirmed B12 deficiency from autoimmune gastritis typically require high-dose oral B12 (1,000-2,000 mcg/day methylcobalamin sublingual) or intramuscular B12 injection to bypass impaired absorption.
The Complete Lab Panel
| Lab Test | Standard Range | Functional Target | Why It Matters for Hashimoto's |
|---|---|---|---|
TSH | 0.4–4.5 mIU/L | 1.0–2.5 mIU/L | Symptom persistence documented in Hashimoto's patients with TSH 2.5–4.5. On levothyroxine: target 1.0–2.0. |
Free T4 | 0.8–1.8 ng/dL | Upper half of range | Low-normal T4 limits conversion to active T3. Target the upper half, not just "within range." |
Free T3 | 2.3–4.2 pg/mL | Upper third of range | The metabolically active hormone. Many symptomatic patients have "normal" FT3 in the lower third. DIO2 polymorphisms impair T4→T3 conversion. |
TPO Antibodies | <35 IU/mL | Declining trend over time | Absolute value matters less than trajectory. >500 IU/mL = significant burden. A 20%+ reduction over 6 months = meaningful response to protocol. |
TgAb (Thyroglobulin Ab) | <20 IU/mL | Declining trend over time | Often elevated alongside TPO-Ab. TgAb-positive, TPO-negative = seronegative Hashimoto's variant. Required for complete antibody picture. |
Vitamin D [25(OH)D] | 30–100 ng/mL | 50–70 ng/mL | VITAL trial 2022: 22% reduction in autoimmune incidence with D3 supplementation. The autoimmune target is substantially higher than the "sufficient" threshold of 30. |
Ferritin | 13–150 ng/mL (F) 24–336 ng/mL (M) | >70–80 ng/mL | Ferritin <30 ng/mL impairs T4→T3 peripheral conversion and drives telogen effluvium (hair shedding). Many Hashimoto's patients are low-normal but functionally deficient. |
Reverse T3 (rT3) | 9.2–24.1 ng/dL | FT3:rT3 ratio >20 | High rT3 competes with FT3 at the receptor, causing cellular hypothyroidism with "normal" labs. Elevated by chronic illness, high cortisol, caloric restriction, and iron deficiency. |
Serum Selenium | 70–150 μg/L | 120–150 μg/L | Low-normal selenium (70–90 μg/L) is insufficient for optimal selenoprotein synthesis and TPO antibody reduction. The CATALYST trial dose (200 mcg selenomethionine) targets the upper half. |
Iron Panel (full) | Lab-specific | Transferrin sat. 25–35% | Serum iron + TIBC + transferrin saturation reveals functional iron deficiency missed by hemoglobin alone. Transferrin sat. <20% = insufficient iron supply. |
hs-CRP | <3.0 mg/L | <1.0 mg/L | Standard "normal" CRP allows significant ongoing inflammation. For autoimmune management, <1.0 mg/L indicates well-controlled systemic inflammation. |
Homocysteine | 5–15 μmol/L | <8 μmol/L | Elevated homocysteine indicates B12/B9 deficiency (common in Hashimoto's due to autoimmune gastritis / B12 malabsorption) and cardiovascular risk. |
Standard: 0.4–4.5 mIU/L
Symptom persistence documented in Hashimoto's patients with TSH 2.5–4.5. On levothyroxine: target 1.0–2.0.
Standard: 0.8–1.8 ng/dL
Low-normal T4 limits conversion to active T3. Target the upper half, not just "within range."
Standard: 2.3–4.2 pg/mL
The metabolically active hormone. Many symptomatic patients have "normal" FT3 in the lower third. DIO2 polymorphisms impair T4→T3 conversion.
Standard: <35 IU/mL
Absolute value matters less than trajectory. >500 IU/mL = significant burden. A 20%+ reduction over 6 months = meaningful response to protocol.
Standard: <20 IU/mL
Often elevated alongside TPO-Ab. TgAb-positive, TPO-negative = seronegative Hashimoto's variant. Required for complete antibody picture.
Standard: 30–100 ng/mL
VITAL trial 2022: 22% reduction in autoimmune incidence with D3 supplementation. The autoimmune target is substantially higher than the "sufficient" threshold of 30.
Standard: 13–150 ng/mL (F) 24–336 ng/mL (M)
Ferritin <30 ng/mL impairs T4→T3 peripheral conversion and drives telogen effluvium (hair shedding). Many Hashimoto's patients are low-normal but functionally deficient.
Standard: 9.2–24.1 ng/dL
High rT3 competes with FT3 at the receptor, causing cellular hypothyroidism with "normal" labs. Elevated by chronic illness, high cortisol, caloric restriction, and iron deficiency.
Standard: 70–150 μg/L
Low-normal selenium (70–90 μg/L) is insufficient for optimal selenoprotein synthesis and TPO antibody reduction. The CATALYST trial dose (200 mcg selenomethionine) targets the upper half.
Standard: Lab-specific
Serum iron + TIBC + transferrin saturation reveals functional iron deficiency missed by hemoglobin alone. Transferrin sat. <20% = insufficient iron supply.
Standard: <3.0 mg/L
Standard "normal" CRP allows significant ongoing inflammation. For autoimmune management, <1.0 mg/L indicates well-controlled systemic inflammation.
Standard: 5–15 μmol/L
Elevated homocysteine indicates B12/B9 deficiency (common in Hashimoto's due to autoimmune gastritis / B12 malabsorption) and cardiovascular risk.
What to Request at Your Next Appointment
Initial workup or annual comprehensive review: TSH, Free T4, Free T3 (specify all three explicitly; "comprehensive thyroid panel" often omits FT3), TPO antibodies, TgAb, 25-Hydroxyvitamin D, ferritin plus full iron panel (serum iron, TIBC, transferrin saturation), hs-CRP, CBC with differential.
For persistent symptoms despite optimized medication, add: Reverse T3 (often not covered by insurance), serum selenium, homocysteine, and fasting insulin with HOMA-IR. Insulin resistance is common in Hashimoto's and compounds metabolic symptoms.
How to Ask Your Doctor for the Right Tests
Many primary care physicians and general endocrinologists routinely order only TSH. This is a known gap between standard-of-care thyroid monitoring and what Hashimoto's patients need. A productive approach with your physician:
Be specific about symptoms: "I have persistent fatigue and brain fog despite TSH in the normal range. I'd like to check Free T3 and Free T4 to see if conversion is optimal."
Reference clinical guidelines: "The ATA guidelines for Hashimoto's on levothyroxine suggest targeting TSH in the lower half of the range for symptomatic patients. My current TSH is 3.2. Could we trial targeting 1.0-2.0?"
Make the case for nutritional labs: "I've read that ferritin below 70 ng/mL impairs T4 to T3 conversion and causes hair loss independently of hypothyroidism. Could we check ferritin and a full iron panel?"
For hs-CRP and Vitamin D, these are standard preventive care labs. Request them at your annual physical if your physician won't add them to a thyroid visit.
In most US states, you can order lab panels directly through LabCorp Patient Direct, Quest Diagnostics Online, or Rupa Health without a physician order. The functional panel outlined here costs approximately $150-300 from direct-to-consumer services.
Frequently Asked Questions
What is the optimal TSH for Hashimoto's?
The functional target is 1.0-2.5 mIU/L for most Hashimoto's patients, and 1.0-2.0 mIU/L for patients on levothyroxine who remain symptomatic. This is referenced in ATA guidelines and supported by quality-of-life outcome data. Some patients feel well at TSH 2.5; others feel their best at TSH 1.0. Individualize with your physician.
Why does my doctor only check TSH?
TSH alone is the standard screening test because it is sensitive and inexpensive. For a Hashimoto's patient with persistent symptoms, TSH alone is insufficient. It does not capture T4 to T3 conversion efficiency, reverse T3 elevation, or where in the range FT3 actually sits. Advocate for Free T4 and Free T3 alongside TSH at monitoring visits.
What Vitamin D level should I target with Hashimoto's?
The functional target is 50-70 ng/mL, substantially higher than the laboratory "sufficient" threshold of 30 ng/mL. The VITAL trial 2022 documented a 22% reduction in autoimmune disease incidence with sustained D3 supplementation. Toxicity requires levels above 150 ng/mL; there is substantial safety margin.
Why does my ferritin look normal but I still feel hypothyroid?
Because "within normal" for ferritin includes values down to 13 ng/mL (women): a level that impairs thyroid peroxidase activity, T4 to T3 conversion, and causes hair loss independently of hypothyroidism. The functional target is above 70-80 ng/mL. Also note: ferritin is an acute-phase reactant and can appear falsely normal in the setting of Hashimoto's inflammation. Always interpret with a full iron panel including transferrin saturation.
Should I test Reverse T3?
Reverse T3 is most useful when you have persistent symptoms despite apparently optimal Free T4 and Free T3, or risk factors including chronic illness, high cortisol, prolonged caloric restriction, or confirmed iron deficiency. It is not part of routine monitoring. Use it to investigate a specific clinical question. Often not covered by insurance.
How often should I test TPO antibodies?
At baseline (diagnosis), then every 6-12 months while monitoring protocol response. The trajectory over 6-12 months is the meaningful signal; month-to-month fluctuation is not. Annual testing is sufficient for patients who have achieved antibody stabilization and symptom control.
What supplements lower TPO antibodies?
Selenium (200 mcg/day selenomethionine) is the Grade A intervention: 40-55% reduction documented in multiple RCTs including the CATALYST trial. Myo-inositol combined with selenium shows synergistic benefit. Vitamin D optimization supports Treg activity. The AIP diet primarily reduces hs-CRP and symptom burden rather than directly lowering antibodies. For persistent high antibodies after foundational interventions, low dose naltrexone is a Tier 3 option targeting TLR4-driven inflammation.
Key Takeaways
- TSH 1.0-2.5 mIU/L is the functional target; on levothyroxine with persistent symptoms, target 1.0-2.0.
- Measure Free T3 and Free T4 alongside TSH. Many symptomatic patients have FT3 in the lower third of the range.
- Vitamin D 50-70 ng/mL, not 30 ng/mL. The autoimmune protective effect requires serum levels well above the bone-health threshold.
- Ferritin above 70-80 ng/mL. Low-normal ferritin impairs T4 to T3 conversion and causes hair loss.
- TPO-Ab trajectory matters more than the absolute number. A 20% or greater reduction over 6 months is a meaningful response signal.
- hs-CRP below 1.0 mg/L is the goal. Ongoing systemic inflammation predicts worse outcomes.
- Selenium toward the upper half of its range. Low-normal selenium is insufficient for optimal selenoprotein function.
This article is for educational purposes only and does not constitute medical advice. Do not adjust thyroid medications based on this guide without physician supervision. Lab targets discussed here reflect functional medicine and integrative endocrinology perspectives and may differ from standard endocrinology guidelines. Always discuss specific dosage recommendations with your doctor. Work with a qualified physician to interpret your lab results and adjust your treatment plan.
Find out which interventions and lab targets belong in your personalized Hashimoto's protocol. Take the free 3-minute AutoimmuneFinder quiz to get your evidence-graded recommendation set.